01 |
TTX |
1 μM |
Blocks voltage-gated sodium channels |
Complete block of action potentials. No effect on plateau depolarizations |
02 |
DNQX |
20 μM |
Blocks glutamatergic AMPA receptors |
No significant effect on plateau depolarizations |
03 |
Strychnine |
20 μM |
Blocks glycinergic receptors |
No significant effect on plateau depolarizations |
04 |
Cocktail of 5 drugs dubbed “Syn. Block” (DNQX, APV, bicuculline, strychnine, and TTX) |
DNQX = 20 μM; APV = 20 μM; Bicucull. = 20 μM; strychnine = 20 μM; TTX = 1 μM |
Blocks glutamatergic (AMPA and NMDA), GABAergic (GABA-A), and glycinergic receptors, as well as the voltage-gated sodium channels |
|
05 |
Octanol |
1 mM |
Blocks gap junctions and hemichannels |
Potently blocks plateau depolarizations |
06 |
Lanthanum |
50 μM |
Blocks connexin hemichannels |
Potently blocks plateau depolarizations |
07 |
Probenecid |
2.5 mM |
Blocks pannexin hemichannels |
No effect on plateau depolarizations |
08 |
Lindane |
50 μM |
Blocks connexin hemichannels |
Potently blocks the number and duration of plateau depolarizations. Small but significant decrease of the plateau amplitude |
09 |
Cocktail of 3 drugs dubbed “MVD” (Mibefradil, Verapamil and Diltiazem) |
Mibefradil = 90 μM; Verapamil = 20 μM; Diltiazem = 20 μM |
Blocks voltage-gated calcium channels |
No effect on the number of depolarizing events, or their duration. A small but statistically significant decrease in plateau amplitude |
10 |
Gadolinium |
25 μM |
Blocks connexin hemichannels |
Potently blocks plateau depolarizations |
11 |
PPADS |
10 μM |
Blocks purinergic receptors |
Decreases the duration of the plateau depolarizations, causing a significant change in the surface area |
12 |
DLFC
|
100 μM |
Blocks ATP production in glia |
Decreases the number of active cells per visual field and the number of events in recordings |